NCT05518123 is a Phase 4 clinical trial of Rimegepant in Migraine, sponsored by Pfizer.

Who is sponsoring NCT05518123?

NCT05518123 is sponsored by Pfizer.

What drugs are being tested in NCT05518123?

Interventions in NCT05518123: Rimegepant, Placebo.

Is NCT05518123 still recruiting?

NCT05518123 is currently completed. Last updated 18 July 2025.

Last reviewed 2025-07-18 · How we verify

NCT05518123

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

Completed Phase 4 Last updated 18 July 2025

What this trial tests

Phase 4 trial testing Rimegepant in Migraine in 658 participants. Completed in 8 July 2025.

Timeline

7 November 2022

Primary endpoint
31 March 2025

8 July 2025

Quick facts

Lead sponsor	Pfizer
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	658
Start date	7 November 2022
Primary completion	31 March 2025
Estimated completion	8 July 2025
Sites	111 locations across Denmark, Italy, Finland, Belgium, Austria, Sweden, United Kingdom, Germany

Drugs / interventions tested

Rimegepant (rimegepant) — full drug profile →
Placebo

Conditions studied

Migraine — all drugs for Migraine →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Migraine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications.
Özge A, Baykan B, Bıçakçı Ş, Ertaş M, et al · · 2024 · cited 11× · PMID 38938785 · DOI 10.3389/fneur.2024.1402569
A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications.
Pozo-Rosich P, López JAG, Lisewski P, Aslan AN, et al · · 2025 · cited 1× · PMID 41255098 · DOI 10.1177/03331024251391378
Does rimegepant prevent migraine attacks in people who have not found other treatments taken by mouth (orally) to work well? A plain language summary of clinical study findings.
Pozo-Rosich P, Gien López JA, Lisewski P, Aslan AN, et al · · 2026 · PMID 42047365 · DOI 10.1080/17581869.2026.2646702

Verify or expand the search:

Other trials of Rimegepant

Trials testing the same drug.

NCT06999252 — Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients · Phase 2 · not yet recruiting
NCT06985342 — Acute Migraine Treatment in the ED With Gepants · Phase 4 · recruiting
NCT06992674 — The R-E-V-I-V-A-L Study · Phase 2 · active not recruiting
NCT06748664 — A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment · Phase 2 · not yet recruiting
NCT06641466 — A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual · Phase 3 · recruiting

Other recruiting trials for Migraine

Currently open trials in the same condition.

NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05518123 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 18 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05518123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing